Case series reveals persistent B cell depletion after rituximab in autoimmune and glomerular diseases, highlighting prolonged remission alongside heightened infection risk.
Persistent B cell depletion is a rare complication of rituximab treatment, mostly affecting patients with exposure(s) to cytotoxic therapies for recurrent diseases. It is characterized by prolonged disease remission and increased infection risk.
No takes yet. Share an insight, caveat, or question.
Efe et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: